Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleCB Insights
Bending Spoons’ acquisition spree and the future of insurance brokerages
View original at cbinsights.comCB Insights - Enterprise Ai Title: Bending Spoons’ acquisition spree and the future of insurance brokerages Date: 2026-09-17 22:30 Source: https://www.cbinsights.com/research/newsletter-september-17/ <p><span style="font-weight: 400;">Below, we break down some of tech’s biggest stories, with analyst perspective on the…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
150+ unicorns are stuck with cap tables at 2021-era valuations nobody would fund again, similar to Miro and Airtable before their sales.
60% confidenceAmong the largest insurance brokerages, only four acquisitions over the past two and a half years have involved AI companies.
60% confidenceThe insurance brokerage industry is not eyeing a fundamental business model change from AI; talent is, and will continue to be, the key strategic differentiator for insurance agencies and brokerages going forward.
60% confidence
Cited in these Via News reports
- AI-Designed Biologics and Personalized mRNA Vaccines: What the Oncology Evidence Supports, and What It Doesn't →
- Agentic AI Reaches the Enterprise Stack: Meta Hires a Database CEO, Seed Money Goes Vertical, and Governance Becomes the Bottleneck →
- AstraZeneca Says Its Data Will Train Better Cancer Drugs. Its Pitch Rests on a Source That Failed Our Check. →
- AstraZeneca's AI 'Lab of the Future' Meets a Crowded Oncology Pipeline: What Is Proven, and What Is Still a Promise →
- AstraZeneca's AI Drug-Design Vision Is Still a Forecast, While Oncology's Near-Term Catalysts Are Conventional →
- AstraZeneca's AI-Designed-Biologics Pitch Is a Forecast, Not a Result: What the Oncology Pipeline Actually Shows →
- AstraZeneca's AI-to-Lab Loop Meets a Crowded Oncology Calendar, and the Evidence for It Is Still Thin →
- Before ESMO 2026, AI's role in cancer drug discovery rests on promises, not yet on measured results →
- Oncology's Q4 Catalyst Season Meets Pharma's AI Pitch: What Is Verified, and What Is Still a Claim →
- The Agent Platform Race Is Being Won in the Plumbing: Authorization Deals, Policy Enforcement and the Limits of AI Arithmetic →
